Patidegib
Patidegib is a hedgehog-pathway blocker made into a skin gel. It is being tested in people with Gorlin syndrome, who grow dozens of basal cell carcinomas, to prevent new tumours without the hair loss, muscle cramps and taste loss that the oral drugs cause.
Overview
Patidegib is the topical formulation of saridegib (IPI-926), a Smoothened inhibitor first developed by Infinity Pharmaceuticals as an oral drug. PellePharm reformulated it as a 2 percent gel applied twice daily to the face. Because Gorlin (basal cell nevus) syndrome is caused by germline PTCH1 loss, every basal cell carcinoma depends on hedgehog signalling, and oral vismodegib prevents them but is poorly tolerated for long-term use.
A phase 2 study in Gorlin syndrome reported fewer new surgically eligible basal cell carcinomas with the gel than with vehicle, and a phase 3 trial followed. It is named on the locally advanced basal cell carcinoma page as the prevention approach for patients with the syndrome.
A cyclopamine derivative that binds Smoothened and blocks hedgehog signalling in the skin; applied as a gel it reaches the basal cells where basal cell carcinomas start without the systemic side effects of oral hedgehog inhibitors. Connects to Smoothened (hedgehog pathway).
1.Patidegib slips into a pocket on Smoothened (hedgehog pathway).
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Patidegib" OR ABSTRACT:"Patidegib" OR TITLE:"Saridegib topical" OR ABSTRACT:"Saridegib topical" OR TITLE:"IPI-926" OR ABSTRACT:"IPI-926") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Patidegib, not a curated reading list.
Similar pages
not linked directly; found by shared links- PathwayBasal cell carcinoma (KEGG map)
Shares Sonidegib, Smoothened (hedgehog pathway), Vismodegib, Locally advanced and metastatic basal cell carcinoma.
- TrialTo Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Shares Vismodegib, Locally advanced and metastatic basal cell carcinoma.
- TrialERIVANCE BCC
Shares Smoothened (hedgehog pathway), Vismodegib, Locally advanced and metastatic basal cell carcinoma.
- Key paperBOLT: two doses of sonidegib in locally advanced or metastatic basal cell carcinoma
Shares Sonidegib, Locally advanced and metastatic basal cell carcinoma.
- TechnologyHedgehog pathway inhibitors
Shares Sonidegib, Vismodegib, Locally advanced and metastatic basal cell carcinoma.
- Key paperERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma
Shares Vismodegib, Locally advanced and metastatic basal cell carcinoma.
- TrialBOLT
Shares Sonidegib, Smoothened (hedgehog pathway), Locally advanced and metastatic basal cell carcinoma.
- TermMedulloblastoma molecular groups (WNT, SHH, group 3, group 4)
Shares Sonidegib, Vismodegib.